A New Combination Chemotherapy with Cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for Advanced Esophageal Cancers.

DOI Web Site Web Site PubMed 6 Citations 18 References
  • YOSHIOKA Takashi
    The Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University
  • GAMOH Makio
    The Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University
  • SHINEHA Ryusaburo
    The Second Department of Surgery, Tohoku University
  • ISHIBASHI Satoru
    The Second Department of Surgery, Tohoku University
  • SHIBATA Hiroyuki
    The Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University
  • SUZUKI Takao
    The Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University
  • MURAKAWA Yasuko
    The Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University
  • KATO Syunsuke
    The Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University
  • SHIMODAIRA Hideki
    The Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University
  • KATO Satoshi
    The Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University
  • ISHIOKA Chikashi
    The Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University
  • KANAMARU Ryunosuke
    The Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University

Bibliographic Information

Other Title
  • New Combination Chemotherapy with Cis diammine glycolatoplatinum Nedaplatin and 5 fluorouracil for Advanced Esophageal Cancers

Search this article

Abstract

Objective The efficacy of a new chemotherapeutic combination consisting of Cis-diammineglycolatoplatinum (Nedaplatin), a derivative of cisplatin (CDDP), and 5-fluorouracil (5FU) was evaluated in patients with advanced esophageal carcinomas. Methods Nedaplatin was administered at a dose of 80 or 100 mg/m2 with 500 ml of saline by slow drip infusion for 120 minutes on day 1.5FU at a dose of 350 or 500 mg/m2 was mixed with 1, 000 ml of saline and administered by continuous infusion for 24 hours on days 1 to 5. Patients or Materials This combination chemotherapy was tried in 17 patients with metastatic, recurrent, or bulky unresectable esophageal cancers. Of these, 15 evaluable patients received at least two courses of chemotherapy. Results The response rates in assessable and all patients were 60% and 52.9%, respectively. Cases with lymph node and liver metastases, as well as primary lesions, showed excellent response to the therapy with positive response rates of 54.5% (6/11), 100% (5/5) and 58.4% (7/12), respectively. The median response duration was 7 (range 3 to 37+) months for patients who achieved a partial response. Adverse drug reactions were limited to three cases of grade 3 toxicity, including allergy, and decreased hemoglobin and platelets, which were well tolerated by the patients. Conclusion The present study thus indicated the combination chemotherapy of Nedaplatin and 5FU to be safe and efficacious for advanced esophageal cancer. Further investigations are clearly warranted.<br>(Internal Medicine 38: 844-848, 1999)

Journal

  • Internal Medicine

    Internal Medicine 38 (11), 844-848, 1999

    The Japanese Society of Internal Medicine

Citations (6)*help

See more

References(18)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top